- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.08. | Elevation Oncology, Inc. - 15-12G, Securities registration termination | 4 | SEC Filings | ||
| 23.07. | NSE - Elevation Oncology, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| ELEVATION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 23.07. | Elevation Oncology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 02.07. | Elevation Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | 133 | PR Newswire | -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting --
-- Expects to file IND application for EO-1022 in 2026... ► Artikel lesen | |
| 06.03. | Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements | 170 | PR Newswire | -- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today | ||
| APOGEE THERAPEUTICS | 76,81 | -0,35 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| ADMA BIOLOGICS | 19,730 | -0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,335 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DISC MEDICINE | 92,00 | +0,16 % | H.C. Wainwright reiterates Buy rating on Disc Medicine stock | ||
| VERA THERAPEUTICS | 49,170 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,300 | 0,00 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 19,010 | -0,31 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| RADIOPHARM THERANOSTICS | 10,630 | 0,00 % | Radiopharm (RADX) Sees Slight Pessimism From Analysts | ||
| KYVERNA THERAPEUTICS | 10,810 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 35,840 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| PRAXIS PRECISION MEDICINES | 276,42 | +2,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,080 | -5,84 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 40,230 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen |
ELEVATION ONCOLOGY INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,362 Euro und damit -0,82 % im Minus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELEVATION ONCOLOGY INC finden Sie auf Wallstreet Online.